Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Multi-Factor Investor model based on the published strategy ...

Johnson & Johnson (NYSE: JNJ) recently released its Q1 earnings, surpassing analyst estimates on both revenue and earnings. The company posted adjusted earnings of $2.77 per share on revenue of $ ...

One of the best pharma stocks to add to your portfolio is Johnson & Johnson (JNJ), a blue chip healthcare company with a long history of rewarding shareholders. It boasts a strong balance sheet ...

Johnson & Johnson (NYSE:JNJ) said that its acquisition of Intra-Cellular Therapies (NASDAQ:ITCI) is expected to be completed on or around April 2, 2025, pending approvals. The company corrected an ...